arrow
E

Eugene D. Kwon

mayo clinic
H指数:69
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Ten-year outcomes of PET-directed salvage nodal radiotherapy and temporary ADT for N1 and M1a hormone-sensitive prostate cancer

PET指导下的挽救性淋巴结放疗联合临时性ADT治疗N1和M1a激素敏感性前列腺癌的十年结果

2026-09-150
OAAI
PSMA-RECAP: [177Lu]Lu-PSMA-617 retreatment in metastatic castration-resistant prostate cancer

PSMA-RECAP:[177Lu]Lu-PSMA-617重复治疗转移性去势抵抗性前列腺癌

2026-08-310
OA
Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing

晚期前列腺癌中潜在可操作基因组改变的演变:基于连续循环肿瘤DNA检测的真实世界分析

CANCERS
IF4.4
2025-09-180
OAAI
Outcomes for [177Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer

[177Lu]Lu-PSMA-617在有和无雄激素受体通路抑制剂联合使用情况下,在转移性去势抵抗性前列腺癌患者中的疗效

2025-08-050
PRE
[177Lu] Lu-PSMA-617 treatment for metastatic castration-resistant prostate cancer (mCRPC) with cerebral and cerebellar metastases

[177Lu] Lu-PSMA-617治疗伴有脑部和脑桥部转移的转移性去势抵抗性前列腺癌(mCRPC)

2025-07-210
PRE
Outcomes for Patients with Metastatic Castration-Resistant Prostate Cancer and Liver Metastasis Receiving [177Lu]Lu- PSMA-617

接受 [177Lu]Lu- PSMA-617治疗的转移性去势抵抗性前列腺癌和肝转移患者的预后

2024-10-300
PRE
Survival Patterns Based on First-site-specific Visceral Metastatic Prostate Cancer: Are Outcomes of Visceral Metastases the Same?

基于第一部位特异性内脏转移性前列腺癌的生存模式: 内脏转移的结果是否相同?

2024-08-012
OAAI
Genomic attributes of prostate cancer across primary and metastatic noncastrate and castrate resistant disease states: a next generation sequencing study of 183 patients
2024-02-273
PRE
Phase II Evaluation of Stereotactic Ablative Radiotherapy (SABR) and Immunity in 11C-Choline-PET/CT-Identified Oligometastatic Castration-Resistant Prostate Cancer
2021-12-0123
OA
Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer
2021-02-0129
OAAI
Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors
2020-12-01118
OAAI